---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-24-000058"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:21.948418+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Keros CEO Seehra becomes Chair; Rovaldi promoted to President effective July 1

## Summary
- CEO Jasbir Seehra appointed Chair of Board, effective July 1, 2024, succeeding Carl Gordon who remains director.
- Christopher Rovaldi promoted to President in addition to COO, effective July 1, 2024, replacing Seehra as President.
- Jean-Jacques Bienaimé appointed Lead Independent Director, effective July 1, with a new $25,000 annual retainer.
- Leadership changes come as Keros prepares for first registrational Phase 3 trial of elritercept (KER-050).

## SEC filing metadata
- accession: 0001664710-24-000058
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/kros-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-24-000058
- JSON: https://secwatch.observer/filing/0001664710-24-000058.json
- Plain text: https://secwatch.observer/filing/0001664710-24-000058.txt

## Key facts
- Executive change
  Carl L. Gordon resigned as Chair of the Board at Keros Therapeutics, Inc..
  - Action: resigned
  - Role: Chair of the Board
  source text: Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm
- Executive change
  Jean-Jacques Bienaimé was appointed as Lead Independent Director at Keros Therapeutics, Inc..
  - Action: appointed
  - Role: Lead Independent Director
  source text: the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm
- Executive change
  Christopher Rovaldi was appointed as President and Chief Operating Officer at Keros Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Operating Officer
  source text: The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471024000058/0001664710-24-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.